Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for ...

Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a ...

Johnson & Johnson has agreed to buy the cancer treatment biotech Halda Therapeutics for $3.05 billion cash, part of a ...

The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology ...

Johnson & Johnson acquires Halda Therapeutics for $3 billion to strengthen its oncology portfolio, focusing on prostate ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding cancer treatment portfolio. Read more here.

Johnson & Johnson said on Monday it would buy privately held Halda Therapeutics for $3.05 billion in cash, aiming to expand ...

Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...

Johnson & Johnson said it will purchase Halda Therapeutics, marking the first major buyout for a cancer drugmaker built ...

Johnson & Johnson announced Monday morning it will acquire New Haven-based Halda Therapeutics for $3.05 billion in cash, the ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...